Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906)
Phase 2
- Conditions
- Advanced non-squamous non-small cell lung cancer without EGFR Mutation
- Registration Number
- JPRN-UMIN000003393
- Lead Sponsor
- Central Japan Lung Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
1) Active infection 2) Fever 3) Serious disease condition 4) Active double cancer 5) Symptomatic brain metastasis 6) Cavity fluid retention difficult to control 7) Severe drug allergy 8) Pregnancy or lactation 9) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method